Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Corbus Pharmaceuticals Hldgs Inc (CRBP)

Corbus Pharmaceuticals Hldgs Inc (CRBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 467,449
  • Shares Outstanding, K 10,687
  • Annual Sales, $ 0 K
  • Annual Income, $ -44,600 K
  • 60-Month Beta 2.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CRBP with:

Options Overview Details

View History
  • Implied Volatility 132.53% ( +5.35%)
  • Historical Volatility 63.85%
  • IV Percentile 95%
  • IV Rank 52.75%
  • IV High 161.86% on 03/06/24
  • IV Low 99.79% on 03/15/24
  • Put/Call Vol Ratio 0.20
  • Today's Volume 6
  • Volume Avg (30-Day) 68
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 2,653
  • Open Int (30-Day) 2,679

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.21
  • Number of Estimates 2
  • High Estimate -0.98
  • Low Estimate -1.43
  • Prior Year -2.05
  • Growth Rate Est. (year over year) +40.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.03 +34.22%
on 04/25/24
45.00 -4.47%
on 04/16/24
+4.84 (+12.69%)
since 04/10/24
3-Month
20.85 +106.14%
on 02/12/24
49.87 -13.80%
on 03/13/24
+20.84 (+94.09%)
since 02/09/24
52-Week
3.03 +1,317.22%
on 11/13/23
49.87 -13.80%
on 03/13/24
+33.68 (+361.76%)
since 05/10/23

Most Recent Stories

More News
Corbus Pharmaceuticals: Q1 Earnings Snapshot

Corbus Pharmaceuticals: Q1 Earnings Snapshot

CRBP : 42.99 (-1.71%)
Corbus Pharmaceuticals: Q4 Earnings Snapshot

Corbus Pharmaceuticals: Q4 Earnings Snapshot

CRBP : 42.99 (-1.71%)
Mira Pharmaceuticals Stock Is Soaring In November... Here's Why

Leveraging a favorable DEA classification for its synthetic analog of THC, Mira Pharmaceuticals could be on an expedited pathway toward commercialization to treat several unmet neurological m

MIRA : 0.7200 (-4.00%)
CARA : 0.7200 (-5.28%)
CRBP : 42.99 (-1.71%)
HRMY : 30.14 (-3.64%)
JAZZ : 109.63 (-3.09%)
Corbus Pharmaceuticals: Q3 Earnings Snapshot

Corbus Pharmaceuticals: Q3 Earnings Snapshot

CRBP : 42.99 (-1.71%)
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

/PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that an...

CRBP : 42.99 (-1.71%)
Corbus Pharmaceuticals: Q2 Earnings Snapshot

Corbus Pharmaceuticals: Q2 Earnings Snapshot

CRBP : 42.99 (-1.71%)
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

/PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today provided a corporate...

CRBP : 42.99 (-1.71%)
Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

/PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that Yuval...

CRBP : 42.99 (-1.71%)
Corbus Pharmaceuticals: Q1 Earnings Snapshot

Corbus Pharmaceuticals: Q1 Earnings Snapshot

CRBP : 42.99 (-1.71%)
Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting

/PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced details of new...

CRBP : 42.99 (-1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic...

See More

Key Turning Points

3rd Resistance Point 47.78
2nd Resistance Point 45.83
1st Resistance Point 44.41
Last Price 42.99
1st Support Level 41.04
2nd Support Level 39.09
3rd Support Level 37.67

See More

52-Week High 49.87
Last Price 42.99
Fibonacci 61.8% 31.98
Fibonacci 50% 26.45
Fibonacci 38.2% 20.92
52-Week Low 3.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar